[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-126277-en":3,"doc-seo-126277-105":31,"detail-sidebar-cat-0-en-105":93},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":22,"language":23,"language_code":24,"site_id":25,"html_lang":24,"table_of_contents":26,"faqs":27,"seo_title":28,"seo_description":14,"update_tm":29,"read_time":30},126277,2336475104736,"Quinn","https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222",8,"Research & Report","Predicting outcome with Intranasal Esketamine treatment - A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)","Treatment-resistant depression (TRD) is a severe condition with substantial social and economic impact. Esketamine Nasal Spray (ESK-NS) is approved for TRD, yet individualized predictors of response remain insufficient. This retrospective multicenter real-world study evaluates sociodemographic and clinical features predicting response using machine-learning in 149 TRD participants, with psychometric assessments at baseline, one month, and three months. Three random-forest models reach 68.53% accuracy at T1 and 66.26% at T2, and 68.60% for remission at T2.","Psychiatry Research 327 (2023) 115378  \nContents lists available at ScienceDirect  \nPsychiatry Research  \njournal [homepage:](homepage: www.elsevier.com/locate/psychres)[ www.elsevier.com/locate/psychres](homepage: www.elsevier.com/locate/psychres)  \nPredicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)  \nMauro Pettorruso a, Roberto Guidotti a, Giacomo d’Andrea a, *, Luisa De Risiob, Antea D’Andrea a, Stefania Chiappini a, Rosalba Carullo a, Stefano Barlati c, d,  \nRaffaella Zanardi e, f, Gianluca Rosso g, Sergio De Filippish, Marco Di Nicola i,j, Ileana Andriolak, Matteo Marcatilil, Giuseppe Nicol`ob, Vassilis Martiadis m, Roberta Bassetti n,  \nDomenica Nucifora o, Pasquale De Fazio p, Joshua D. Rosenblat q, r, s, t, Massimo Clericil, u, Bernardo Maria Dell’Osso v, Antonio Vita c, d, Laura Marzetti a, Stefano L. Sensi a,  \nGiorgio Di Lorenzo w, x, Roger S. McIntyre q, r, s, t, y, Giovanni Martinotti a, z, the REAL-ESK Study Group1  \na Department of Neurosciences, Imaging and Clinical Sciences, Universit`a degli Studi G. D’Annunzio, Chieti, Italy b Department of Mental Health and Addiction, ASL Roma 5, Rome, Italy  \nc Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy  \nd Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy  \ne Mood Disorder Unit, Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy f Department of Clinical Neurosciences, University Vita-Salute San Raffaele, Milan, Italy  \ng Department of Neurosciences Rita Levi Montalcini, University of Torino, Turin, Italy h Neuropsychiatric Clinic, Villa Von Siebenthal, Genzano di Roma, Italy  \ni Department of Neurosciences, Section of Psychiatry, Universit`a Cattolica del Sacro Cuore, Rome j Department of Psychiatry, Fondazione Policlinico Universitario \"Agostino Gemelli\" IRCCS, Rome k Universit`a degli Studi di Bari Aldo Moro, Italy  \nl Department of Mental Health and Addiction, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy m ASL Napoli 1 Centro, Department of Mental Health, Napoli, Italy  \nn Department of Mental Health and Addiction Services, Niguarda Hospital, Milan, Italy  \no MDSMA Taormina-Messina Sud ASP di Messina, Italy  \np Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy q Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada  \nr Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada s Department of Psychiatry, University of Toronto, Toronto, ON, Canada  \nt Braxia Health, Canadian Centre for Rapid Treatment Excellence (CRTCE), Mississauga, ON, Canada u School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy  \nv Department of Biomedical and Clinical Sciences Luigi Sacco and Aldo Ravelli Center for Neurotechnology and Brain Therapeutic, University of Milan, Milano, Italy w Chair of Psychiatry, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy  \nx IRCCS Fondazione Santa Lucia, Rome, Italy  \ny Brain and Cognition Discovery Foundation, Toronto, ON, Canada  \nz Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK  \nA R T I C L E I N F O  \nKeywords: TRDEsketamine  \nA B S T R A C T  \nTreatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about  \n* Corresponding author at: Department of Neurosciences, Imaging and Clinical Sciences, Universit`a degli Studi G. D’Annunzio, Via dei Vestini, 66100 Chieti, Italy. E-mail address: giacomo.dandrea1993@gmail.com (G. d’Andrea).  \n1 A list of authors of the consortia and their affiliations appears","cbCaifSOnKHF61xs","https://ap.wps.com/l/cbCaifSOnKHF61xs","pdf",3614309,7,1,11,"English","en",105,"# Background\n## Study design and data collection\n## Machine-learning models and predictive performance\n## Predictors of response and remission\n## Clinical implications and limitations","[{\"question\":\"What is the main goal of the ESK-LEARNING study?\",\"answer\":\"To identify sociodemographic and clinical features that predict individual patient response and remission to intranasal esketamine in treatment-resistant depression using machine-learning methods.\"},{\"question\":\"How were outcomes and predictors measured over time?\",\"answer\":\"Psychometric data were collected at baseline, one month (T1), and three months (T2) after treatment initiation using MADRS, BPRS, HAM-A, and HAMD-17.\"},{\"question\":\"Which factors were associated with better response and remission?\",\"answer\":\"Severe anhedonia, anxious distress, mixed symptoms, and bipolarity were found to positively predict response and remission.\"}]","Predicting outcome with Intranasal Esketamine treatment - A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING) | PDF",1785904224,28,{"code":4,"msg":32,"data":33},"ok",{"site_id":25,"language":24,"slug":34,"title":13,"keywords":35,"description":14,"schema_data":36,"social_meta":88,"head_meta":90,"extra_data":92,"updated_unix":29},"predicting-outcome-with-intranasal-esketamine-treatment-a-machine-learning-three-month-study-in-treatment-resistant-depression-esk-learning-126277","",{"@graph":37,"@context":87},[38,55,70],{"@type":39,"itemListElement":40},"BreadcrumbList",[41,45,49,52],{"item":42,"name":43,"@type":44,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":46,"name":47,"@type":44,"position":48},"https://docshare.wps.com/document/","Document",2,{"item":50,"name":12,"@type":44,"position":51},"https://docshare.wps.com/document/research-report/",3,{"item":53,"name":13,"@type":44,"position":54},"https://docshare.wps.com/document/predicting-outcome-with-intranasal-esketamine-treatment-a-machine-learning-three-month-study-in-treatment-resistant-depression-esk-learning-126277/126277/",4,{"url":53,"name":13,"@type":56,"author":57,"headline":13,"publisher":59,"fileFormat":62,"inLanguage":24,"description":14,"dateModified":63,"datePublished":64,"encodingFormat":62,"isAccessibleForFree":65,"interactionStatistic":66},"DigitalDocument",{"name":9,"@type":58},"Person",{"url":42,"name":60,"@type":61},"DocShare","Organization","application/pdf","2026-08-18","2026-08-05",true,{"@type":67,"interactionType":68,"userInteractionCount":20},"InteractionCounter",{"@type":69},"ViewAction",{"@type":71,"mainEntity":72},"FAQPage",[73,79,83],{"name":74,"@type":75,"acceptedAnswer":76},"What is the main goal of the ESK-LEARNING study?","Question",{"text":77,"@type":78},"To identify sociodemographic and clinical features that predict individual patient response and remission to intranasal esketamine in treatment-resistant depression using machine-learning methods.","Answer",{"name":80,"@type":75,"acceptedAnswer":81},"How were outcomes and predictors measured over time?",{"text":82,"@type":78},"Psychometric data were collected at baseline, one month (T1), and three months (T2) after treatment initiation using MADRS, BPRS, HAM-A, and HAMD-17.",{"name":84,"@type":75,"acceptedAnswer":85},"Which factors were associated with better response and remission?",{"text":86,"@type":78},"Severe anhedonia, anxious distress, mixed symptoms, and bipolarity were found to positively predict response and remission.","https://schema.org",{"og:url":53,"og:type":89,"og:title":13,"og:site_name":60,"og:description":14},"article",{"robots":91,"canonical":53},"index,follow",{"doc_id":7,"site_id":25},{"code":4,"msg":5,"data":94},[95,99,103,107,112,117,121,124,129,132,136],{"id":21,"doc_module":4,"doc_module_name":47,"category_name":96,"show_sort_weight":97,"slug":98},"Story & Novel",90,"story-novel",{"id":48,"doc_module":4,"doc_module_name":47,"category_name":100,"show_sort_weight":101,"slug":102},"Literature",80,"literature",{"id":54,"doc_module":4,"doc_module_name":47,"category_name":104,"show_sort_weight":105,"slug":106},"Exam",70,"exam",{"id":108,"doc_module":4,"doc_module_name":47,"category_name":109,"show_sort_weight":110,"slug":111},5,"Comic",60,"comic",{"id":113,"doc_module":4,"doc_module_name":47,"category_name":114,"show_sort_weight":115,"slug":116},6,"Technology",50,"technology",{"id":20,"doc_module":4,"doc_module_name":47,"category_name":118,"show_sort_weight":119,"slug":120},"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":47,"category_name":12,"show_sort_weight":122,"slug":123},30,"research-report",{"id":125,"doc_module":4,"doc_module_name":47,"category_name":126,"show_sort_weight":127,"slug":128},9,"Religion & Spirituality",20,"religion-spirituality",{"id":127,"doc_module":4,"doc_module_name":47,"category_name":130,"show_sort_weight":127,"slug":131},"World Cup","world-cup",{"id":133,"doc_module":4,"doc_module_name":47,"category_name":134,"show_sort_weight":133,"slug":135},10,"Lifestyle","lifestyle",{"id":137,"doc_module":4,"doc_module_name":47,"category_name":138,"show_sort_weight":108,"slug":139},19,"General","general"]